Recent developments in the pharmacological treatment of Parkinson’s disease

By Tuite Paul   Riss Jennifer  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1335-1352

Informa Healthcare

Access to resources Recommend Favorite

TNF- antagonists for the treatment of Crohn’s disease

By Kam L.Y.   Targan S.R.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 615-622

Informa Healthcare

Access to resources Recommend Favorite

Toxicity of infliximab in the course of treatment of Crohn’s disease

By Bratcher Jason M   Korelitz Burton I  

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 9-16

Informa Healthcare

Access to resources Recommend Favorite

Severe myalgia associated with mesalazine treatment in a child with Crohn’s disease

By Peršić Mladen   Palčevski Goran   Slavić Irena   Vlahović-Palčevski Vera  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 3, 2007-03 ,pp. : 315-317

Springer Publishing Company

Access to resources Recommend Favorite

Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohn’s Disease

By Peter D. Han   Russell D. Cohen  

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1767-1777

Adis International

Access to resources Recommend Favorite